Erlotinib [183321-74-6]

Catalog number: HY-50896_500mg
Brand: MedChem Express
Packing: 500 mg
Other sizes: Other sizes available
Price: € 120.00
Expected delivery time: 10 days
Quantity:

Product specifications for - Erlotinib [183321-74-6]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 183321-74-6
Properties: 
Purity: >98%
Molecular Formula: C22H23N3O4
Molecular weight: 393.44
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: Erlotinib (OSI-744, NSC 718781, R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. IC50 value: 2 nM [1] Target: EGFR in vitro: Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 uM) induces apoptosis in DiFi humancolon cancer cells [1]. Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 uM. [2] Erlotinib HCl(2 uM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells [2].Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition [3]. in vivo: At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice [1]. Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate [3].
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: HY-50896
Viruses. 2020 Jun 10;12(6):628. Read more
Thorac Cancer. 2020 Oct;11(10):2858-2866. Read more
Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Read more
PLoS One. 2018 Jun 14;13(6):e0199208. Read more
Oncotarget. 2017 Dec 2;8(68):112313-112329. Read more
Oncol Rep. 2016 Dec;36(6):3588-3596. Read more
Oncogene. 2021 Jul;40(30):4884-4893. Read more
Oncogene. 2017 May 11;36(19):2643-2654. Read more
Neurobiol Dis. 2020 Aug;142:104961. Read more
Nat Immunol. 2022 Feb;23(2):251-261. Read more